Clinical trials: Low-risk Papillary Thyroid Cancer
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Thyroid Cancer, Regret
Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer
This randomized, active-controlled, non-inferiority trial is scheduled to begin in May 2025 and will continue until June 2027. Inclusion criteria: (1) Patients with low-risk papillary thyroid cancer without lymph node metastasis…
- Trial name
- NCT06804863
- Testing
- Postoperative Regret Reduction through Immediate Quality of Life Intervention
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- West China Hospital